NCT03280563 2025-11-10
MORPHEUS HR+BC
Hoffmann-La Roche
Phase 1/2 Completed
Clinical Trials
8 trialsNCT05054374 2025-05-23
A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT03344536 2022-11-25
A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT02657343 2022-08-01
An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT02983604 2019-08-07
GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer
Gilead Sciences
Phase 1/2 Terminated
NCT02345772 2018-02-20
Neohttp
Western Regional Medical Center
Phase 1/2 Terminated
NCT01202591 2016-02-11
GLOW
AstraZeneca
Phase 1/2 Completed
NCT00903006 2015-02-02
Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 1/2 Terminated